Comprehensive medication guide to {drug} including estimated pricing, availability information, side effects, and how to find it in stock at your local pharmacy.
Ebglyss (Lebrikizumab-lbkz) is a biologic medication made by Eli Lilly for the treatment of moderate-to-severe atopic dermatitis (eczema) in adults and adolescents aged 12 and older who weigh at least 40 kg (88 lb). It is approved for patients who are candidates for systemic therapy — meaning topical treatments alone haven't been enough to control their symptoms. Ebglyss is administered as a subcutaneous injection that patients can self-administer at home after proper training.
Ebglyss is a humanized monoclonal antibody that specifically targets and blocks interleukin-13 (IL-13), a key cytokine that drives type 2 inflammation. IL-13 plays a central role in the skin barrier dysfunction, inflammation, itching, and thickening seen in atopic dermatitis. By binding to IL-13 and preventing it from signaling, Ebglyss reduces the inflammatory cascade responsible for eczema flares, helping to clear skin and relieve itch.
The loading dose is 500 mg (two 250 mg injections) at Week 0 and Week 2, followed by 250 mg every 2 weeks through Week 16, then 250 mg every 4 weeks for maintenance.
Ebglyss (Lebrikizumab-lbkz) has a findability score of 35 out of 100, meaning it can be quite difficult to locate. As a newly launched specialty biologic approved by the FDA in September 2024, Ebglyss is not stocked at most retail pharmacies. It is almost exclusively dispensed through specialty pharmacies, which require prior authorization from your insurance. Supply is still ramping up following early manufacturing delays that initially postponed FDA approval in 2023. If your dermatologist prescribes Ebglyss, expect the specialty pharmacy coordination process to take several days to a few weeks.
Struggling to find {drug} in stock? We'll call the pharmacies, sit on hold, and find you one that can fill your prescription.
Ebglyss is typically prescribed by dermatologists and allergists/immunologists who specialize in managing moderate-to-severe atopic dermatitis. Pediatric dermatologists may also prescribe it for adolescents aged 12 and older. Because most insurance plans require prior authorization and evidence that other treatments have been tried first, your prescribing doctor will usually need to submit documentation of your treatment history. Telehealth consultations are available for some follow-up visits.
No. Ebglyss is not a controlled substance and has no DEA scheduling. It is a biologic medication that does not carry abuse or dependence potential. However, it does require a prescription and is dispensed through specialty pharmacies.
Eye-related side effects are notably common with Ebglyss. Contact your doctor if you experience persistent eye pain, redness, or vision changes. Serious but rare side effects include hypersensitivity reactions, herpes zoster (shingles), and parasitic infections.
No formal drug interaction studies have been conducted. As a monoclonal antibody, Ebglyss is not expected to directly interact with most common medications.
Ebglyss is an important new option for people living with moderate-to-severe atopic dermatitis, especially those who haven't responded well to other treatments. As a targeted IL-13 inhibitor, it offers a focused approach to reducing inflammation and itch. The main challenges right now are availability and cost — it's a specialty-pharmacy-only biologic with a high cash price, though Eli Lilly's savings programs can significantly reduce out-of-pocket costs. If you're having trouble finding Ebglyss, Medfinder can help you locate specialty pharmacies that carry it.
%2C%20Color%3DOriginal.png)
